Comparative Pharmacology
Head-to-head clinical analysis: ESTAZOLAM versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTAZOLAM versus SERAX.
ESTAZOLAM vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and CNS depression.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
1-2 mg orally at bedtime.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Terminal elimination half-life: 10-24 hours (mean ~17 hours); prolonged in elderly and hepatic impairment.
Clinical Note
moderateEstazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate."
Clinical Note
moderateEstazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Estazolam."
Clinical Note
moderateEstazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Estazolam."
Clinical Note
moderateEstazolam + Cyclosporine
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal: ~90% as metabolites, <1% unchanged. Fecal: small amount, ~10%.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Estazolam."